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Background: Corticoids have potent anti-inflammatory effects, which may help in relieving pain and dysfunction
associated with lumbar canal stenosis. We assessed the effectiveness of a decreasing-dose regimen of oral corticoids
in the treatment of lumbar canal stenosis in a prospective, double-blind, randomized, placebo-controlled trial.
Results: Sixty-one patients with lumbar canal stenosis (50–75 years; canal area < 100 mm2 at L3/L4, L4/L5, and/or
L5/S1on magnetic resonance imaging; and claudication within 100 m were electronically randomized to an oral
corticoid group (n = 31) or a placebo group (n = 30). The treatment group received 1 mg/kg of oral corticoids daily,
with a dose reduction of one-third per week for 3 weeks. Patients and controls were assessed by the Short Form 36
Health Survey, Roland–Morris Questionnaire, 6-min walk test, visual analog scale, and a Likert scale. All instruments
showed similar outcomes for the corticoid and placebo groups (P > 0.05). Obese patients exhibited more severe
symptoms compared with non-obese patients. L4/L5 stenosis was associated with more severe symptoms compared
with stenosis at other levels.
Conclusion: The oral corticoid regimen used in this study was not effective in the treatment of lumbar canal stenosis.
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Symptomatic lumbar canal stenosis is characterized by
degenerative alterations in several structures of the
vertebral segment, including the zygapophyseal joint,
flavum, articular capsule, and intervertebral disc. These
alterations decrease the vertebral canal area, resulting in
pressure on the neural structures [1] that is clinically
manifested as low back pain [2] and lower limb pain
that worsens while walking and improves with rest, a
presentation called neurogenic claudication [3].
As the population ages, the number of symptomatic
patients is expected to increase. Indeed, symptomatic
lumbar canal stenosis is the primary reason for surgical
treatment of the spine in patients over 60 years of age
[4]. Treatment of spinal stenosis begins with guidance* Correspondence: jnatour@unifesp.br
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article, unless otherwise stated.about the disease, adequate pain control, physical therapy,
and exercise [5] to maintain activities of daily living. If
these measures fail, surgery may be necessary, particularly
in patients with exercise intolerance, walking difficulty,
and/or urinary incontinence [6]. While more than 50%
patients respond satisfactorily to drug treatment and
physiotherapy [7], those with severe stenosis and major
neurological involvement may require surgery [8].
Because spinal stenosis most frequently affects the
elderly, a patient group with a high surgical complication
rate, an oral regimen can dramatically improve overall
treatment safety. To this end, we assessed the efficacy of
oral corticoids for the treatment of lumbar canal stenosis.Patients and methods
This prospective, double-blind, randomized controlled
study was approved by the research ethics committee of
Universidade Federal de Sao Paulo (CEP 1892/10). Sixty-d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Lumbar canal area
L3/L4 L4/L5 L5/S1
Mean 103 84 84
Standard deviation 25.31 15.36 15.79
Rodrigues and Natour Journal of Negative Results in BioMedicine 2014, 13:13 Page 2 of 6
http://www.jnrbm.com/content/13/1/13one patients were electronically randomized to the drug
treatment or placebo control group. Opaque envelopes
were used to ensure the secrecy of the allocation. The
drug treatment group was administered corticoids at
1 mg/kg/day with a one-third dose reduction per week.
The control group was administered placebo for the
same period. All patients were assessed at four time
points during the study: baseline (T0), at the end of
treatment (week 3, T3), and at 6 and 12 weeks after
study initiation (T6 and T12, respectively). All patients
were permitted paracetamol (750-mg tablets) up to 3
times a day as a rescue analgesic. Total paracetamol
intake and response were also assessed. The patient and
the assessor were blinded to treatment.
All patients were assessed by the following instruments:
canal area calculation; a 10-cm visual analog scale (VAS)
for pain; the Roland–Morris Questionnaire for function
[9]; the 6-min walk test for function; the Short Form
(SF)-36 Health Survey for quality of life; paracetamol
consumption during the study and a 5-point Likert-type
scale to evaluate the patient satisfaction with the treat-
ment where the following question was done to patient:
“Thinking in how you are before treatment, how do you
fell now?” and they can choose between 5 options (“much
better”, “slightly better”, “unchanged”, “slightly worse”,
and “much worse”) – the Likert scale was not applied for
the initial assessment (T0).
Inclusion criteria were the presence of claudication
within less than 100 m and the presence of at least two
of the following lower limb symptoms: pain, weakness,
burning, tingling (associated with or independent of
lower back pain), and a vertebral canal area of <100 mm2
in at least one of the levels assessed (L3/L4, L4/L5, L5/S1)
by the Hamanishi technique [10].
The exclusion criteria were as follows: decompensated
diabetes mellitus, systemic hypertension, decompensated
cardiopathy, systemic diseases affecting the lower limbs,
neuromuscular diseases, use of corticoids in the past
3 months, previous lumbar or thoracic surgeries, cogni-
tive deficits that compromise the capacity to understand
or interpret the questionnaires, spondylolisthesis (except
degenerative), degenerative scoliosis with a Cobb angle
of >10°, degenerative pathologies in the hip or knee that
can interfere with gait, and a history of total or partial
arthroplasty in the hip and/or knee joint.
The canal area was calculated on the basis of maximum
anteroposterior (a) and mediolateral (b) area using mag-
netic resonance imaging (MRI). After calculating these
values, they were individually divided by 2 and multiplied
by π as show in the following formula:
Area ¼ a=2ð Þ  b=2ð Þ  3:14 constant
The constant is 0.8 when the canal is circular, 0.7 when
the canal is elliptical, 0.6 in the presence of facetarycompression, and 0.5 when the compression is caused by
the disc and facets [10].
The sample size was chosen to yield a statistical power
of 80% and a α of 5% when comparing VAS scores
between groups, assuming a group standard deviation
of 2 cm and a minimum mean intergroup difference
of 2 cm. We used Student’s t-test to compare continu-
ous variables with a homogenous distribution across
groups. Generalized linear models and unbalanced 2-
factor ANOVA were used to test the temporal effect of
medication and interaction between the test period and
medication. Tukey’s test was used for 2 by 2 comparisons
between time period and medication for the measurement
points. Pearson’s correlation analyses were performed
to assess the relationships among clinical variables. In
all statistical tests, P-values of <5% were considered
statistically significant.Results
All 61 eligible patients, including 31 in the corticoid
group and 30 in the placebo group, completed the study.
There were no group differences in female: male ratio
and there were no significant differences in height and
weight between groups for the males and females. The
mean and standard deviation for age was 58.23 (6.38) in
the corticoid group and 58.33 (6.19) in the control
group. Regarding BMI the mean and standard deviation
for the corticoid group and control group was 25.97
(5.16) and 27.90 (4.53) respectively, and no difference
were found between groups.
The mean and standard deviation of the stenosis at the
three levels assessed, namely L3/L4, L4/L5, and L5/S1, are
presented in Table 1.
The VAS scores for pain suggested a mild improvement
in both groups at T3, as indicated by the lower scores
compared with those at baseline (T0); however, these
scores increased thereafter, with no significant change
across test periods between groups (Table 2).
The Roland–Morris questionnaire was administered at
baseline (T0), after the 3-week drug/placebo trial (T3),
and at 6 and 12 weeks after study initiation (T6, T12)
(Table 2). The scores suggested a slight improvement in
the corticoid group at the beginning of treatment; however,
they were not significantly different from those for the
placebo group. In fact, no significant differences in total
scores were observed within or between groups for any
individual assessment period.
Table 2 VAS score, Roland–Morris score and 6-min walk
test distance before and after corticoid treatment
T0 T3 T6 T12
VAS score (cm) P-value 0.56
CORTICOID 7.68 5.68 6.71 6.61
PLACEBO 7.07 5.50 5.17 5.97
P-VALUE 0.30 0.81 0.02* 0.37
Roland–Morris score P-value 0.40
CORTICOID 16.16 12.77 14.71 14.81
PLACEBO 15.27 14.73 13.80 13.80
P-VALUE 0.46 0.25 0.53 0.52
6-minute walk test (m) P-value 0.73
CORTICOID 367.39 379.97 346.8 352.6
PLACEBO 388.83 391.50 389.4 395
P-VALUE 0.36 0.62 0.07 0.08
VAS: visual analog scale; *p value statistically significant.
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American Thoracic Society standards on a 22-m track
with patients walking as fast as possible, also showed no
significant improvement in both groups. In fact, the total
distance travelled by the corticoid group decreased by
approximately 40–50 m between T3 and T6 and T12
(Table 2). Because this assessment depends on muscular
structure, the male and female subgroups were separately
compared; this analysis also indicated no benefit of
corticoids (not shown).
The SF-36 questionnaire assesses current health
conditions, with higher values corresponding to a better
condition. The SF-36 scores for our patients suggested
small differences in some of the eight domains during
the study period; however, the final values at T6 and
T12 were similar between groups (Table 3). Separate
comparisons by gender also did not reveal significant
differences in condition between groups (not shown).
Regarding the paracetamol use as a rescue analgesic
between groups over the 21-day drug/placebo adminis-
tration period, we found that the corticoid group intakeTable 3 Short form 36 domain scores before and after cortico
T0 T3
Corticoid Placebo Corticoid Pl
FUNCTIONAL CAPACITY 33.55 26.27 42.35 38
PHYSICAL LIMITATION 19.35 17.50 44.52 48
PAIN 28.06 31.60 46.39 43
GENERAL HEALTH STATUS 45.00 39.63 47.65 45
VITALITY 45.06 45.33 51.77 51
SOCIAL ASPECTS 46.68 56.58 60.58 68
EMOTIONAL ASPECTS 35.47 34.67 50.54 59
MENTAL HEALTH 49.81 49.73 55.74 55was 19.42 (11.79) and the control group intake was
19.63 (11.29) and no significant difference was observed
between groups (p = 0.94).
The Likert-type scale, wherein patients were instructed
to document how they were feeling after treatment
(much better, slightly better, unchanged, slightly worse,
or much worse) also indicated no significant benefits of
corticoids.
The body mass index (BMI) show a low correlation
with VAS for pain, (r = 0,34 and p = 0.035) Roland
Morris scores (r = 0,27 and p = 0.041), six minute walk test
(r = 0,31 and p = 0.039) and SF-36 (r = 0,22 and p = 0.031).
Showing that increase in BMI did not lead to more pain
or poor function and quality of life.
Regarding the canal area we found a low correlation
between lumbar canal stenosis at L3/L4 and more para-
cetamol consumption (r = -0,30 and p =0,016) and pain
subscale of SF-36 (r = 0,25 and p = 0.049) showing that
smaller canal area at L3/L4 leads to pain increase and
makes patient’s to consume more analgesic medication.
Stenosis at L4/L5 shows a low correlation with VAS
for pain (r = 0.28 and p = 0.027), showing that patients
with stenosis at L4/L5 level have worse pain.
Discussion
The oral corticoid regimen tested in this study provided
no significant pain relief or benefits to motor function
in patients with lumbar canal stenosis. The primary
structures contributing to the decrease in spinal canal
area and many of the symptoms of spinal stenosis are
the intervertebral disc, zygapophyseal joint, flavum, and
venous plexus [10]. However, not all patients that
present with signs of stenosis on spinal MRI also
present with clinical symptoms [11]. Inflammation of
these structures will also compress the cauda equina
roots within the vertebral canal and as they pass
through neural foramen [12]. In this study, the patients
presented with diffuse symptoms in lower limbs and it
was not possible to define a myotome for each patient.
However, Schonstrom and colleagues concluded thatid treatment
T6 T12
acebo Corticoid Placebo Corticoid Placebo P value
.17 38.71 43.17 37.26 41.67 0.49
.83 18.55 31.67 20.16 26.27 0.74
.70 36.48 44.20 43.42 42.00 0.55
.20 45.94 46.93 45.87 45.07 0.85
.13 46.94 46.00 47.90 45.23 0.99
.37 65.73 55.25 53.74 52.42 0.21
.30 60.21 65.56 56.13 53.33 0.90
.47 55.48 59.00 55.23 52.93 0.93
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in patients with symptomatic lumbar canal stenosis
[11]. This study assessed the movement of joints that
could mimic claudication due to stenosis by altering
function at the hip or knee [12]; however, patients with
symptomatic alterations that could influence gait were
excluded from the study. The present study also did
not include patients with fibromyalgia or depression,
comorbidities that can amplify symptoms [13].
In this study, the area of stenosis did not influence
evolution of the disease, and similar to the findings of
Zeifang, we found no relationship between the distance
walked and canal area. Also, in accord with our study,
Thornes et al. [14] found that gender did not influence
the clinical response. In the present study, excess weight
worsened prognosis and directly influenced patient per-
formance in the 6-min walk test, a result not consistent
across studies. Crosgrove et al. [15] reported that BMI
was not predictive of treatment response. As in the
current study, Briggs et al. [16] reported that patients
with a high BMI reported more severe pain, but these
patients did show clinical improvement after epidural
corticoid treatment. Many of the clinical variables exam-
ined in the current study, such as gender, BMI, canal
diameter, and walking capacity, have also been examined
previously. In the current study, canal diameter neither
influenced clinical status nor predicted therapeutic
response. On the basis of canal diameter assessments,
Campbell et al. [17] tried to identify patients who would
best respond to epidural corticoids, obviating the need
for surgical treatment. Although they used a different
intervention, all patients used epidural corticoids, and the
results showed that canal diameter was not predictive of
treatment response. In accord with our study, patients
with L4/L5 stenosis were more symptomatic, albeit with
no statistically significant differences in disease evolution.
Our study included cases of degenerative spondylolisth-
esis, all between L4/L5. This eventually causes stenosis of
the cauda equina roots [15,16]. In the present study, all
patients with spondylolisthesis were female, Sengupta et al
[18] concluded that there was little difference in efficacy
among treatments, regardless of the degree of slippage.
This study attempted to identify an effective oral medica-
tion regimen for the management of spinal stenosis, while
maintaining safety by using a decreasing-dose regimen.
While this treatment appeared safe, with no obvious
adverse events, it was not effective for pain or movement
deficits. The effectiveness of corticoids in providing relief
from this syndrome has been tested several times, most
often when applied locally, and the clinical response
has been highly variable [17,19-26]. Campbell et al. [17]
reported that canal diameter is not predictive of response
to epidural steroid injection in patients with lumbar canal
stenosis. Ng et al. [27] reported no effect of corticoidsin a study of patients with lumbar canal stenosis that
compared anesthetics plus epidural corticoids with
anesthetics alone. While these results are in general
agreement with ours, Sayegh et al. [28] report clinical
improvement with epidural corticoids. The reasons for
these discrepancies remain to be explored, although it
should be noted that our assessment instruments were
the same as those used in many of the aforementioned
studies, and all have been validated for the study of
stenosis symptomology and relief [28-40].
Obesity, often due to a sedentary lifestyle, is associated
with loss of sagittal balance, changes in muscle strength,
and a greater weight load on vertebral discs, all of which
are likely to exacerbate degeneration. These patients are
more susceptible to painful conditions and generally
carry a poorer prognosis for most diseases. In this study
as well, we found that patients with a higher BMI were
more symptomatic, suggesting that weight loss is one
safe noninvasive therapy that may improve symptoms
and possibly obviate the need for surgery.
The structures compression in lumbar canal stenosis
leads to two changes: one caused by mechanical compres-
sion and another by venous dilatation and the venous
blood retention can lead to local vascular inflammation
and subsequent pain. These changes can cause neuropathic
pain that can recruit inflammatory mediators enhancing
the inflammation component. Probably the mechanical
compression and edema during gait are the main causes
of pain and inflammatory component is only a secondary
adjunct in this disease [41]. We assume it, although we
cannot prove that the inflammatory component is the
least important.
Studies showing no effect of these potent anti-
inflammatory drugs on stenosis symptoms suggest that
inflammation is not important for symptom expression
and that mechanical and anatomical alterations are
more likely explanations. However, we do not know how
effective this particular dose regimen was at decreasing
inflammation around the stenosis sites; therefore, we
cannot exclude a beneficial effect of other more efficacious
and tolerable anti-inflammatory drugs.
Conclusions
This placebo-controlled study indicates that a tapering
regimen of oral corticoids, starting at 1 mg/kg daily, is
not effective regarding pain, function, quality of life,
analgesic consumption or satisfaction with the treatment
in patients with lumbar canal stenosis when compared
to placebo. Obese patients with lumbar canal stenosis
show more pain or poor function and quality of life.
Lumbar canal stenosis at L3/L4 leads with more analgesic
consumption as compared with stenosis in other levels
and lumbar canal stenosis at L4/L5 is more painful as
compared with stenosis in other levels.
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 The use of oral corticoids is not effective in the
treatment of lumbar canal stenosis.
 Obese patients with lumbar canal stenosis show
more pain or poor function and quality of life.
 Lumbar canal stenosis at L3/L4 leads with more
analgesic consumption as compared with stenosis in
other levels.
 Lumbar canal stenosis at L4/L5 is more painful as
compared with stenosis in other levels.
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